🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to scientists.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million new cases annually. Notably increased rates are observed in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval represents a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

According to results released by a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This places it at an comparable level with the typical regimen, which combines an injection and a pill. The trial involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians on the front lines have expressed optimism. Access to a single-dose, oral treatment like this is hailed as a "game-changer" for gonorrhoea control. This is viewed as crucial to lessen the impact of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.